Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Trimipramine

Plain-language summaryIntrigue 50 / 100

Trimipramine (Surmontil) is the odd duck of the tricyclic family. A single methyl group on the side chain disrupts its ability to block the serotonin and norepinephrine pumps, so it does almost none of the standard tricyclic action. Instead its effects come from heavy histamine receptor blockade plus blocking a basket of serotonin, alpha-1, and dopamine receptors. The result is a strongly sedating drug used mainly for depression with prominent insomnia. It is one of the few antidepressants that does not suppress REM sleep. Approved by the FDA in 1979, it remains in use mostly in Europe. The mechanism is interesting precisely because it shows that an antidepressant does not necessarily need monoamine reuptake inhibition to work. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Unusual non-transporter TCA with narrow but genuine probe value for mechanism dissection

Look, trimipramine is genuinely unusual among TCAs, and thats actually the only reason it earns a spot in a serious research library at all. Most tricyclics work by hammering SERT and NET: imipramine, amitriptyline, nortriptyline, all of them. Trimipramine does something different. SERT Ki sits around 150 nM and NET Ki is an almost useless 2400 nM, which means the monoamine transporter story basically drops out. What’s left is extremely potent H1 antagonism (Ki ~0.27 nM, comparable to first-generation antihistamines), strong 5-HT2A and alpha-1 blockade, and meaningful D2 antagonism. That pharmacological profile makes it an interesting tool for one specific job: dissecting what TCAs actually do when you remove the transporter component.

We think the bench utility here is real but narrow. If you’re investigating whether TCA antidepressant effects are truly transporter-dependent, or you want to understand the separate contributions of H1 and D2 blockade to sedation, sleep architecture, or antipsychotic-adjacent activity, trimipramine is a legitimate reference point. Riemann et al. in the early 1990s showed it preserved slow-wave sleep without the REM suppression typical of SERT-active TCAs, which is genuinely interesting and hasn’t been replicated often enough. That’s the kind of signal worth chasing if sleep architecture is your question.

What we don’t like: this is a 1979 FDA approval with a mechanism that’s been understood for decades. The H1 story isn’t new. D2 antagonism isn’t new. The weak-transporter TCA angle is a curiosity more than a frontier. There’s no recent surge of interest, no emerging indication that elevates it, and the clinical literature is thin compared to amitriptyline or nortriptyline. The depression and insomnia data mostly predates modern trial standards, and we’re not aware of serious ongoing programs studying it in genuinely novel contexts.

The differentiation story is honestly pretty weak outside that specific probe application. For sedation research you’d compare against doxepin (similarly potent H1, more evidence in primary insomnia), quetiapine (D2 and H1 profile backed by a much larger evidence base), or mirtazapine (cleaner H1 with better tolerability data across modern trials). Trimipramine doesn’t dominate any of those comparisons except in the non-transporter TCA niche. The pharmacokinetics are also messy: half-life spans 16 to 40 hours and CYP2D6, CYP2C19, and CYP3A4 all participate, which complicates clean interpretation in multi-compound bench work.

Honestly, if your research question is specifically what TCA pharmacology looks like without the transporter contribution, trimipramine is your molecule. That’s a real question with real mechanistic weight. But if you’re casting wider, there are better targets at almost every other point in this space. The score reflects both the genuine probe utility and the limited scope of that utility.

Novelty

20

Mechanism promise

40

In-category differentiation

42

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Trimipramine’s methyl substitution almost abolishes SERT and NET activity, leaving an unusually pure H1/D2/5-HT2A antagonism profile that gives it real but narrow utility as a reference probe for dissecting non-transporter TCA effects. Low novelty as a 1979 approval with fully understood pharmacology anchors the score; bench value for specific mechanistic questions provides the floor.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (sedating tertiary amine)

A sedating tertiary amine TCA with weak SERT and NET activity; the principal effect is dopaminergic and antihistaminergic.

Abstract

Trimipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; CAS 739-71-9; molecular formula C20H26N2; molecular weight 294.43) is a 2-methylated dibenzazepine TCA approved by the FDA in 1979 under the trade name Surmontil. The methyl substitution at the propanamine’s beta carbon disrupts transporter binding: SERT Ki approximately 150 nM, NET Ki approximately 2400 nM, both several orders of magnitude weaker than amitriptyline or imipramine. The therapeutic effect is therefore primarily attributed to potent H1 (Ki approximately 0.27 nM, comparable to first-generation antihistamines), 5-HT2A, alpha-1, and D2 antagonism. The compound is among the most sedating TCAs in clinical use and is used preferentially in depression with severe insomnia. Plasma half-life is 16 to 40 hours; metabolism is via CYP2D6, CYP2C19, CYP3A4. Used as a reference compound for non-transporter TCA mechanism research; the H1 and dopaminergic profiles distinguish it from typical TCA pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-222Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clomipramine

Plain-language summaryIntrigue 64 / 100

Clomipramine (Anafranil) is a tricyclic antidepressant with one chlorine atom added to imipramine, a small change that flips the selectivity sharply toward serotonin. It is in fact the most potent serotonin reuptake blocker in the entire tricyclic class, with affinity rivaling modern SSRIs. The active leftover after liver metabolism then shifts steady-state activity back toward norepinephrine, so the drug ends up doing both jobs over a 24-hour period. It is the only tricyclic with FDA approval for OCD and remains a third-line option for severe OCD when SSRIs fail. The usual tricyclic burdens (sedation, anticholinergic effects, cardiac risk in overdose) all apply. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

The gold-standard TCA for OCD research but a closed mechanistic frontier with deep evidence and low novelty

Look, clomipramine is one of those compounds where the resume is genuinely impressive but the research horizon has mostly closed. Developed at Geigy in the early 1960s and FDA-approved in 1989 specifically for OCD, it’s been the clinical anchor in treatment-resistant obsessive-compulsive disorder for over three decades. The SERT Ki of roughly 0.28 nM is remarkable for a TCA. Nothing else in the class touches it. And the parent/metabolite pharmacology has a quietly interesting wrinkle: clomipramine is SERT-dominant, but CYP3A4 and CYP2C19-driven demethylation produces N-desmethylclomipramine, a NET-preferring secondary amine, so at steady state you get dual monoaminergic coverage without deliberately engineering it. Thats a legitimately non-trivial pharmacokinetic story.

But none of that is new. The SERT mechanism was worked out decades ago. The OCD indication is mature to the point where the main clinical question is how it compares to SSRIs in treatment-resistant cases, and that question has been asked and partially answered many times over. The off-target burden, muscarinic block, H1 antagonism, alpha-1 and sodium channel activity, makes clomipramine a dirty probe for anything requiring clean SERT signal. If you need a SERT-selective tool in a model system, you’re reaching for citalopram or escitalopram, not this.

Where clomipramine still earns real bench value is as a reference standard in OCD neurobiology. The serotonin hypothesis of OCD is actually more complex than it sounds: there’s ongoing work around 5-HT2A contributions, orbitofrontal circuit modulation, and the genuinely unresolved question of why SERT saturation matters more in OCD than in other anxiety-adjacent disorders. Clomipramine is the clinical anchor for those comparisons. We also think the cataplexy research angle is underappreciated; it remains one of the few compounds with both mechanistic plausibility and real clinical signal in narcolepsy-associated cataplexy, and that’s a small but legitimate research context.

Honestly, the evidence quality here is as high as it gets. Decades of RCTs, multi-site replication, clear regulatory validation. But thats almost the problem: when evidence is this mature, the interesting questions are mostly downstream of the compound, not about it. What we don’t like about recommending this as a primary research focus is that a bench investigator picking it up today is almost certainly asking a comparative or clinical question, not a mechanism-frontier question. That makes it a solid reference tool and a useful historical benchmark. It’s not where serious research resources go to find new answers.

Novelty

20

Mechanism promise

25

In-category differentiation

45

Evidence quality

75

Translational signal

70

Research bench value

55

Rationale Clomipramine scores high on evidence quality and translational signal (FDA-approved, decades of replicated OCD RCTs, reference-standard status) but low novelty and mechanism scores drag the overall down hard; the SERT story is fully mature and the off-target burden makes it a poor clean probe for mechanism work despite its unique clinical niche.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (chlorinated tertiary amine)

A chloro-substituted TCA with the most potent SERT inhibition in the class; the only TCA with FDA approval for OCD.

Abstract

Clomipramine (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 303-49-1; molecular formula C19H23ClN2; molecular weight 314.85) is a 3-chloro-substituted analog of imipramine developed at Geigy and approved by the FDA in 1989 under the trade name Anafranil. The chloro substitution shifts transporter selectivity sharply toward SERT (SERT Ki approximately 0.28 nM, the most potent in the TCA class; NET Ki approximately 38 nM). The active metabolite N-desmethylclomipramine (formed via CYP3A4/CYP2C19) is a NET-preferring secondary amine, producing balanced steady-state monoaminergic activity from a SERT-dominant parent. Off-target activity parallels other tertiary amine TCAs: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 19 to 37 hours. The compound is the only TCA with FDA approval for obsessive-compulsive disorder, an indication where the SSRI class typically requires higher doses; clomipramine remains a benchmark in treatment-resistant OCD. Used as the reference SERT-potent TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-220Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Protriptyline

Plain-language summaryIntrigue 41 / 100

Protriptyline (Vivactil) is a secondary-amine tricyclic antidepressant from 1967 with one defining quirk: it is activating rather than sedating, which is the opposite of nearly every other drug in the class. The activating profile comes from preferential norepinephrine pump blockade combined with relatively little antihistamine activity. That made it historically useful for depressed patients with hypersomnia who needed alertness rather than further sedation. It has a long half-life because the liver metabolizes it slowly. Rarely prescribed now, displaced by SNRIs like duloxetine that achieve similar activation with much better tolerability. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

A 1967-approved TCA with a niche activating profile and almost no modern research frontier

Look, protriptyline is a real drug with a real effect. FDA approved in 1967, still prescribed, pharmacologically coherent. The case for it has always rested on a single differentiating fact: among the tricyclics, it doesn’t sedate. Most of the class leans heavily sedating via H1 blockade, but protriptyline’s relatively low H1 affinity and its NET-dominant profile (Ki around 1.4 nM at the norepinephrine transporter versus roughly 20 nM at SERT) tip the balance toward activation. That matters clinically, particularly in depression complicated by hypersomnia or narcolepsy-related mood disorder. The half-life situation is unusual too: 54 to 92 hours is long even by TCA standards, driven by sluggish CYP2D6 metabolism, which creates both a forgiving dosing window and a complicated clearance picture when coadministering.

Here’s the thing though: none of that is news. The pharmacology was described and characterized decades ago. The NET-over-SERT selectivity angle has been studied far more rigorously in compounds like reboxetine and atomoxetine, and the wakefulness-promoting space now belongs to orexin-pathway agents, modafinil, and the solriamfetol class. If you’re building a research program around activating antidepressant pharmacology, you’re not reaching for protriptyline as your probe. It’s burdened by the full TCA liability profile: muscarinic blockade, sodium channel effects, alpha-1 antagonism, narrow therapeutic index. These are not features that help you isolate a mechanism.

The evidence base is approved-drug-real, which means there’s clinical data going back to the 1960s. But TCA-era trials dont meet modern methodological standards. You’re looking at small, non-blinded, poorly-controlled studies by today’s metrics. Multi-decade literature exists, but a lot of it is descriptive case series or comparisons to other TCAs, not placebo-controlled designs with preregistered endpoints. The narcolepsy-depression comorbidity literature is genuinely thin and mostly observational.

We think the honest bench value here is narrow: if youre specifically studying secondary amine TCA pharmacokinetics, CYP2D6-driven extended half-life effects, or the NET-dominant TCA subclass as a historical reference point, protriptyline has a role. That’s a specific niche, not a broad research priority. For anything involving the activating-antidepressant mechanism today, the tools have moved on. Protriptyline remains useful the way a well-characterized historical reference standard is useful: occasionally, deliberately, and not as a centerpiece of a serious contemporary program.

Novelty

10

Mechanism promise

20

In-category differentiation

25

Evidence quality

45

Translational signal

48

Research bench value

28

Rationale Protriptyline scores low across novelty and differentiation because it is a mid-century TCA with no mechanism surprise and no serious modern competition driving renewed investigation; its higher NET selectivity is real but bupropion and modern SNRIs have absorbed that research territory entirely. Evidence quality and translational signal get modest credit for FDA approval and clear clinical effect, but neither dimension rescues the compound’s place in a contemporary research priority stack.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine, activating)

A secondary amine TCA distinguished by activating rather than sedating subjective profile; useful in depression with hypersomnia.

Abstract

Protriptyline (N-methyl-3-(5H-dibenzo[a,d]cyclohepten-5-yl)propan-1-amine; CAS 438-60-8; molecular formula C19H21N; molecular weight 263.38) is a secondary amine TCA approved by the FDA in 1967 under the trade name Vivactil. Distinct among TCAs for an activating subjective profile that contrasts with the sedation typical of the class; the activating profile is attributed to relatively higher NET-to-SERT selectivity and reduced H1 antagonism. NET Ki approximately 1.4 nM, SERT Ki approximately 20 nM. Plasma half-life is exceptionally long (54 to 92 hours) owing to slow CYP2D6 metabolism. The activating profile makes protriptyline a niche choice for depression with prominent hypersomnia or fatigue, including narcolepsy-associated depression where the wakefulness-promoting effect is therapeutic. Off-target activity is otherwise typical of secondary amine TCAs: muscarinic, mild H1, alpha-1, and sodium channel block. Approved for major depressive disorder; rarely first-line today owing to TCA-class limitations. Used as a reference compound for activating TCA pharmacology and in narcolepsy-related comorbidity research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-221Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Imipramine

Plain-language summaryIntrigue 60 / 100

Imipramine is historically the most important antidepressant ever made: Roland Kuhn at Geigy noticed in 1958 that this antihistamine candidate unexpectedly lifted depressed patients’ moods, which kicked off the entire monoamine theory of depression and the modern era of psychiatric pharmacology. Mechanically it blocks the serotonin and norepinephrine pumps in roughly balanced fashion, while also blocking acetylcholine, histamine, and alpha-1 adrenergic receptors as side activities. Today it sees mostly historical and academic use, plus a niche role in nocturnal enuresis (bedwetting) in children. The cardiac sodium channel block makes overdose lethal, which is one reason SSRIs displaced it once they became available. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

The 1958 prototype TCA, historically foundational but superseded by cleaner tools at every research axis

Look, imipramine is the Adam compound of synthetic antidepressant pharmacology. Roland Kuhn’s 1958 Geigy observation that the dibenzazepine scaffold relieved depressive symptoms launched the monoamine hypothesis and gave the field its first real conceptual framework. That history is genuinely significant. What the rubric asks is something different: how compelling is THIS compound as an active bench target right now, and the honest answer is, not very.

The mechanism is completely characterized and has been for decades. SERT inhibition at roughly 1 nM Ki, NET inhibition at ~21 nM, plus a well-mapped off-target profile covering muscarinic M1, H1, alpha-1 adrenergic, and voltage-gated sodium channels. The off-target hits that were once clinical liabilities remain liabilities now, not research opportunities. Nobody’s building a new program around imipramine’s anticholinergic activity when you can isolate those mechanisms cleanly elsewhere with better-characterized probes.

The differentiation problem is the sharpest drag here. Imipramine is superseded by its own active metabolite: desipramine is a cleaner, more NET-selective secondary amine that most investigators reach for when they want a TCA probe for norepinephrine transporter work specifically. For SERT-selective work, the entire SSRI class exists. For balanced dual inhibition, duloxetine and venlafaxine offer better tolerability and considerably cleaner pharmacology. Imipramine loses on almost every axis to something developed after it. Thats not a knock on historical significance, its just the reality of a 67-year-old compound in a mature drug class where every successive generation improved on the scaffold.

Where it retains real value is narrow: positive control in pharmacology assays requiring the canonical first-generation TCA, CYP2D6 and CYP2C19 probe substrate work, and research programs specifically examining the TCA class for historical comparison or mechanistic archaeology. The evidence base is genuinely solid, sixty-plus years of replicated clinical data, FDA approval across MDD, enuresis, and panic disorder, robust translational signal. But that signal describes clinical applications modern practice has largely moved past, and solid old evidence doesn’t make a compound interesting.

We think the honest landing for imipramine is important reference compound with narrow active bench utility. The evidence quality and translational signal keep the score from falling further, but the novelty floor and severely penalized differentiation pull it squarely into the same tier as piracetam: historically central to the field, currently deprioritized by most investigators chasing something with more headroom.

Novelty

15

Mechanism promise

22

In-category differentiation

15

Evidence quality

65

Translational signal

65

Research bench value

45

Rationale Imipramine scores hard at the bottom of novelty and differentiation because it’s a 1958 compound outcompeted by its own active metabolite (desipramine) and the entire SSRI/SNRI class; evidence quality and translational signal are genuinely solid but for indications modern practice has largely moved past, producing an overall that sits in the same tier as piracetam.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (tertiary amine; first synthetic antidepressant)

The first synthetic antidepressant; the parent compound of the TCA class and the historical reference for monoamine theory of depression.

Abstract

Imipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 50-49-7; molecular formula C19H24N2; molecular weight 280.41) is a dibenzazepine tertiary amine TCA developed at Geigy by Roland Kuhn in 1958, the first synthetic compound demonstrated to relieve depressive symptoms in clinical trial. The historical observation underpinned the catecholamine hypothesis of depression and launched modern psychopharmacology. SERT and NET affinities are balanced (SERT Ki approximately 1 nM, NET Ki approximately 21 nM); the active metabolite desipramine is a NET-preferring secondary amine. Off-target activity parallels amitriptyline: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 11 to 25 hours; metabolism is via CYP2D6 and CYP2C19. Approved for major depressive disorder; clinical use today focuses on enuresis (bedwetting) in children (low-dose for anticholinergic and alpha-1 effects on bladder) and panic disorder. The TCA cardiotoxicity profile is the principal limitation. Used as the historical reference TCA and the prototype monoamine reuptake inhibitor in pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-218Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Desipramine

Plain-language summaryIntrigue 53 / 100

Desipramine (Norpramin) is the active leftover of imipramine, FDA-approved in 1964, and the most norepinephrine-selective tricyclic antidepressant ever brought to market. The shift in selectivity comes from removing one methyl group from imipramine. The strongly noradrenergic profile makes it one of the more activating tricyclics and useful in attention deficit research, although it never gained an ADHD label. Compared to its parent it has lower anticholinergic and antihistamine burden, so it is somewhat better tolerated, but it shares the cardiac conduction problems of the whole tricyclic class and overdose is dangerous. Used in treatment-resistant depression and some neuropathic pain protocols. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

The canonical NET-selective TCA; useful as a noradrenergic reference probe but essentially exhausted as a research frontier

Look, desipramine is about as established as it gets in the TCA class. FDA-approved in 1964, it’s been the reference standard for NET-selective tricyclic pharmacology for sixty years. That dual status, canonical probe on one hand and dated workhorse on the other, is exactly what drives the score here.

The NET selectivity is real and it matters. A Ki of roughly 0.83 nM at NET versus 17 nM at SERT gives you a selectivity ratio around 20-fold, which is genuinely useful if you’re trying to dissect noradrenergic from serotonergic contributions in a mixed-reuptake experiment. Compared to imipramine, the parent compound, desipramine sheds meaningful muscarinic (M1 Ki around 200 nM) and H1 load while keeping the NET hit clean. For any investigator running catecholamine reuptake assays, building pharmacological controls, or studying NE dynamics in pain or ADHD-relevant circuits, its position as the canonical NET-selective TCA is hard to displace within that specific context. Thats the bench case for having it in the library.

But thats also where the excitement ends. The mechanism, NET reuptake inhibition, has been understood for sixty years. The binding kinetics are fully characterized, the downstream noradrenergic effects are mapped, and the CYP2D6/CYP2E1 metabolism profile is textbook. What we dont like is that atomoxetine and reboxetine both exist now, offering higher NET selectivity without the TCA off-target load. For pure noradrenergic questions, those compounds have largely superseded desipramine except in historical comparisons or when the TCA scaffold itself is under study.

The evidence base is enormous. Multiple phase 3 trials, decades of replicated clinical data, strong meta-analytic signal for MDD. Translational signal is unambiguous in the sense that it works in people and that fact is exhaustively documented. But from a research novelty standpoint, a large evidence base on a 60-year-old compound means less remaining question to answer. There’s no frontier in the depression indication, the neuropathic pain angle is mature, and the ADHD off-label use lives in the shadow of better-characterized and more selective tools.

We think desipramine earns its place in the library as a reference compound and nothing more. Investigators comparing noradrenergic agents, running assay controls, or building pharmacological models of NE reuptake will want it on the shelf. For anything asking a genuinely new question about human biology, the novelty and mechanism scores drag the overall to where it belongs: a well-characterized, historically important, presently limited research tool.

Novelty

18

Mechanism promise

28

In-category differentiation

40

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Desipramine scores well on evidence and translational signal because its pharmacology is thoroughly characterized over six decades, but those same qualities crush its novelty and mechanism scores. Its bench value is real but narrow: it functions as a reference standard for NET-selective TCA comparisons, not as a frontier compound worth pursuing for new biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of imipramine; the most NET-selective TCA in clinical use.

Abstract

Desipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine; CAS 50-47-5; molecular formula C18H22N2; molecular weight 266.38) is the N-desmethyl active metabolite of imipramine, approved by the FDA in 1964 under the trade name Norpramin. The compound is the most NET-selective TCA in clinical use (NET Ki approximately 0.83 nM, SERT Ki approximately 17 nM, ratio approximately 20). Off-target activity is reduced compared to imipramine: muscarinic (M1 Ki approximately 200 nM), H1 (Ki approximately 60 nM), and alpha-1 (Ki approximately 100 nM) antagonism are all weaker than the parent compound, producing a cleaner profile though still TCA-like. Plasma half-life is 15 to 24 hours; metabolism is via CYP2D6 and CYP2E1. Approved for major depressive disorder; used at higher doses (150 to 300 mg) for moderate-severe depression, at lower doses for ADHD (off-label) and neuropathic pain. Sodium channel block and consequent cardiotoxicity in overdose remain limitations. Used as the canonical NET-selective TCA in mechanism studies and as a reference compound for noradrenergic pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-219Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nortriptyline

Plain-language summaryIntrigue 56 / 100

Nortriptyline (Pamelor, Aventyl) is the active leftover of amitriptyline, sold separately after FDA approval in 1964. The body strips one methyl group off amitriptyline to produce nortriptyline, and that small change shifts the drug toward blocking the norepinephrine pump preferentially with much less serotonin activity. It also drops the muscarinic and antihistamine load somewhat, which makes it more tolerable than the parent compound. Among older tricyclics it has the cleanest defined therapeutic blood-level window (50 to 150 ng/mL), which means clinicians can dose it precisely with a blood test rather than guessing. Used for depression, neuropathic pain, and migraine prevention. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

A well-characterized legacy TCA with real bench utility but minimal novelty and largely superseded clinical standing

Look, nortriptyline is what happens when pharmacology matures past a compound. Approved in 1964, it’s the N-desmethyl metabolite of amitriptyline, and that metabolic parentage is itself telling: the original compound was already considered a workhorse before nortriptyline entered independent clinical use. The mechanism is completely mapped. NET Ki around 4 nM, SERT closer to 18 nM, meaningful H1 antagonism, reduced but real muscarinic load. Every branch of that receptor profile has been studied to exhaustion across multiple decades in multiple labs. Thats not a criticism of the compound’s history; it just means a serious investigator isn’t going to find mechanistic surprises here.

Where nortriptyline does outperform amitriptyline is tolerability, specifically the lower anticholinergic burden (M1 Ki roughly 150 nM versus 18 nM for the parent), and that difference is real and clinically meaningful. But the comparison set matters. Against modern SNRIs like duloxetine for neuropathic pain, or against varenicline for smoking cessation, nortriptyline is second-line or lower across nearly every approved and off-label indication. It hasn’t defined its class; it refined a position within a class that’s mostly been vacated by newer chemotypes.

The evidence quality is actually one of the stronger aspects of the profile. Sixty years of clinical data, well-established therapeutic plasma monitoring windows (50 to 150 ng/mL), CYP2D6 metabolism characterized in detail, interaction profiles documented across hundreds of polypharmacy combinations. That depth of evidence is genuinely useful for some research designs and shouldn’t be dismissed. The translational signal is also real: nortriptyline works for depression, works for neuropathic pain, and the smoking cessation signal is well-replicated even if the effect size is modest against better alternatives.

What we think is most honest here: nortriptyline retains specific research value as the canonical secondary amine TCA reference compound. If you’re studying NET-preferring reuptake inhibition in a TCA scaffold, or comparing anticholinergic burden across tricyclic structures, it’s the right tool. That use case is narrow but legitimate, and it’s what keeps the bench_value score from bottoming out. But as an object of primary research interest, honestly, there isn’t much frontier left. The compound doesn’t unlock new biology, the indication space is saturated with better options, and the mechanism has no unexplored angles that the literature hasn’t already addressed multiple times. Score accordingly.

Novelty

18

Mechanism promise

22

In-category differentiation

28

Evidence quality

68

Translational signal

62

Research bench value

55

Rationale Nortriptyline scores low on novelty and mechanism because it is a 60-year-old TCA with a thoroughly mapped pharmacology; it earns back points on evidence quality and translational signal given decades of real clinical use, and modest bench_value credit as the canonical secondary amine TCA reference compound in mechanistic studies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of amitriptyline; a NET-preferring TCA with a more favorable side effect profile.

Abstract

Nortriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropan-1-amine; CAS 72-69-5; molecular formula C19H21N; molecular weight 263.38) is the N-desmethyl active metabolite of amitriptyline, marketed independently as Pamelor and Aventyl after FDA approval in 1964. As a secondary amine TCA, the compound exhibits substantially greater NET selectivity than amitriptyline (NET Ki approximately 4 nM, SERT Ki approximately 18 nM) and reduced muscarinic antagonism (M1 Ki approximately 150 nM versus 18 nM for amitriptyline), producing a cleaner side effect profile. H1 antagonism remains significant (Ki approximately 10 nM) and contributes to residual sedation, but the anticholinergic burden is meaningfully lower. Plasma half-life is 18 to 35 hours; metabolism is via CYP2D6 (primary). Approved for major depressive disorder; widely used at low dose (10 to 75 mg) for chronic pain, neuropathy, and as a smoking cessation aid (off-label). Therapeutic plasma concentrations are well-defined (50 to 150 ng/mL) and routinely monitored, distinguishing nortriptyline from most modern antidepressants. Used as the canonical secondary amine TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-217Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Mianserin

Plain-language summaryIntrigue 47 / 100

Mianserin is the older European cousin of mirtazapine, developed at Organon in the 1960s and marketed across Europe and Asia from 1976 onward. It was never approved in the United States. Like mirtazapine it boosts norepinephrine and serotonin output by blocking the auto-brake on those neurons rather than blocking the reuptake pumps. The differences are subtle: mianserin has a wider spread of off-target receptor activity and a small but historically significant risk of bone marrow suppression, which is part of why mirtazapine ultimately replaced it in most markets. Mianserin remains useful as a research tool for understanding the alpha-2 adrenergic receptor mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Superseded tetracyclic antidepressant with limited modern research appeal beyond mirtazapine comparison work

Look, mianserin is the compound mirtazapine quietly replaced. Organon developed it in the 1960s, got it onto the European and Asian market in 1976, and then spent the next two decades iterating toward a safer, cleaner successor. That successor is mirtazapine. The story of mianserin is, in a meaningful sense, the story of what had to be fixed to get there.

The mechanism is genuinely interesting in outline: alpha-2 adrenergic auto- and heteroreceptor antagonism drives monoaminergic disinhibition in a way thats actually pharmacologically elegant compared to older tricyclics. You also get 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism in the mix. But every one of those receptor interactions is better characterized in mirtazapine, and mirtazapine does it without the agranulocytosis and aplastic anemia risk that haunted mianserin’s clinical career — estimated at roughly 1 in 1500 to 1 in 5000 cases, which is hard to ignore when a structurally similar compound with a cleaner safety profile exists.

The evidence base is real. Decades of European clinical use, multiple controlled trials, established PK (half-life 21-61 hours, CYP2D6 metabolism, active demethyl-mianserin metabolite). This isnt a compound with thin preclinical-only data. But the evidence is aging, the trials are mostly pre-2000, and virtually no active research programs are centering mianserin as a primary object of study. The literature is large because it was used, not because researchers are still reaching for it.

What bench value mianserin retains is narrow. It works as a reference compound in alpha-2 pharmacology comparisons and as a historical control when studying tetracyclic antidepressant mechanisms. If your research question specifically involves comparing first- versus second-generation tetracyclics, or quantifying the receptor-selectivity improvements that mirtazapine achieved, then mianserin is the natural comparator. Outside that framing, its hard to construct a reason to run an experiment with mianserin when mirtazapine exists and is more widely available.

We dont think this belongs on a frontier research shortlist. The novelty is low, the differentiation is negative relative to its own successor, and the research signal it carries is historical rather than prospective. Serious investigators working in adrenergic or tetracyclic antidepressant pharmacology probably already know where mianserin fits. For anyone else, the compound earns a file entry and not much more.

Novelty

18

Mechanism promise

28

In-category differentiation

18

Evidence quality

58

Translational signal

55

Research bench value

30

Rationale Mianserin’s core mechanism is well-understood and has been materially improved upon by mirtazapine, which retains the pharmacologically interesting alpha-2 antagonism while shedding the agranulocytosis liability; novelty and differentiation scores drag the overall down hard. Evidence quality and translational signal are real but historically bounded and largely irrelevant to active research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tetracyclic alpha-2 adrenergic antagonist

A first-generation tetracyclic antidepressant; the structural and mechanistic precursor to mirtazapine.

Abstract

Mianserin (1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; CAS 24219-97-4; molecular formula C18H20N2; molecular weight 264.37) is a tetracyclic antidepressant developed at Organon in the 1960s and marketed in Europe and Asia from 1976 (never FDA approved for the US market). The compound is the structural and mechanistic precursor to mirtazapine, sharing the alpha-2 adrenergic auto/heteroreceptor antagonism that increases monoaminergic release. Mianserin additionally exhibits 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism but with a less favorable receptor selectivity profile than mirtazapine. Notable for a higher incidence of agranulocytosis and aplastic anemia than mirtazapine (estimated 1 in 1500 to 1 in 5000 cases) which contributed to its replacement in clinical practice. Plasma half-life is 21 to 61 hours; metabolism is via CYP2D6 with active demethyl-mianserin metabolite. Used as a reference tetracyclic and alpha-2 antagonist in mechanism studies; less common in clinical use today owing to mirtazapine availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-214Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Maprotiline

Plain-language summaryIntrigue 42 / 100

Maprotiline (Ludiomil) is a tetracyclic antidepressant from Ciba-Geigy, approved in the US in 1980, that blocks the norepinephrine pump selectively while having very little effect on serotonin. That makes it pharmacologically distinct from the standard tricyclic antidepressants of its era, even though its side-effect profile (dry mouth, constipation, sedation) looks similar because it still blocks histamine and acetylcholine receptors as a side hobby. Its most notorious problem is seizure risk, which is the highest of any antidepressant and goes up sharply at high doses or with rapid titration. That alone has pushed it to the back of the prescribing line; few clinicians use it now when newer NRIs like atomoxetine are available. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

A 1980 selective NRI being steadily replaced by cleaner, safer antidepressants with less seizure risk

Look, maprotiline is one of those compounds that made sense in 1980 and progressively less sense after that. Ciba-Geigy’s bridged anthracene scaffold gave it unusually selective NET inhibition — Ki around 11 nM, essentially silent at SERT — which was a reasonable pharmacological achievement when dual-mechanism TCAs were the baseline. The long plasma half-life, 21 to 52 hours, comes from that same rigid scaffold resisting CYP metabolism, which is actually an interesting structural story. We don’t want to dismiss the chemistry entirely.

But the mechanism, as a research object, isn’t doing anything new. Single-target NET reuptake inhibition is well-understood territory. Reboxetine does it cleaner. Atomoxetine does it cleaner. Viloxazine is the newer re-examination of that same noradrenergic thesis, with a more favorable safety window and growing pediatric/adult ADHD literature. Maprotiline’s H1 affinity (Ki approximately 2 nM) and muscarinic activity pile on a TCA-like side effect burden without any of the putative benefits that make mirtazapine’s noradrenergic plus H1 profile actually useful. It occupies an awkward middle ground: too dirty to be a clean NRI probe, not dirty enough to have the clinical versatility of older TCAs.

The seizure risk is the real problem for a research library context. At approximately 0.4 percent seizure incidence at therapeutic doses — the highest of any commonly used antidepressant — any in vitro or in vivo model involving maprotiline has to account for intrinsic CNS excitability effects that are off-target noise for most noradrenergic questions. That’s not a disqualifier for all studies, but it narrows the bench utility considerably.

Evidence quality is decent in the narrow sense: this is an approved drug with multi-site 1970s-80s clinical data, not a peptide riding on single-lab preclinical. But those trials were conducted under standards that wouldn’t pass modern scrutiny, effect sizes were modest, and there’s been no serious modern clinical reinvestigation. The translational signal exists — it works as an antidepressant, full stop — but that fact is not particularly interesting in 2025 when we have SSRIs, SNRIs, mirtazapine, and increasingly bupropion all offering better benefit-risk profiles for the same indication.

Honestly, the only scenario where maprotiline earns serious bench time is if a researcher specifically needs the long half-life pharmacokinetics as a variable, or is doing historical comparative work on NRI mechanisms. We dont see a compelling reason to prioritize it over cleaner NRI tools. It’s worth documenting in the library for completeness, but the score should reflect that the research conversation has largely moved on.

Novelty

22

Mechanism promise

20

In-category differentiation

12

Evidence quality

45

Translational signal

50

Research bench value

30

Rationale Maprotiline’s selective NET inhibition is mechanistically coherent but unremarkable, and its differentiation is actually negative — the seizure liability and TCA-like adverse profile make it strictly worse than modern comparators on most dimensions. Evidence quality is moderate given its approval-era trial base, but the compound is declining in use, not rising in research interest.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tetracyclic norepinephrine reuptake inhibitor

A tetracyclic NRI with TCA-like side effects but selective noradrenergic action; significant seizure risk at high dose.

Abstract

Maprotiline (N-methyl-9,10-ethanoanthracene-9(10H)-propylamine; CAS 10262-69-8; molecular formula C20H23N; molecular weight 277.40) is a tetracyclic norepinephrine reuptake inhibitor developed at Ciba-Geigy and approved in the US in 1980 under the trade name Ludiomil. NET affinity is approximately 11 nM with very weak SERT activity (Ki greater than 1 microM), making the compound a selective NRI structurally classed with the tetracyclics owing to its bridged anthracene scaffold. Significant H1 (Ki approximately 2 nM) and muscarinic activity produces a side effect profile resembling tricyclic antidepressants: sedation, anticholinergic effects, weight gain. Plasma half-life is 21 to 52 hours, the longest of the antidepressant class, owing to the bridged scaffold’s resistance to CYP metabolism. The compound carries the highest seizure risk of any commonly used antidepressant (approximately 0.4 percent at therapeutic doses, increasing sharply in overdose). The seizure risk and TCA-like adverse profile have led to declining use in favor of mirtazapine and SSRIs.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-215Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Levomilnacipran

Plain-language summaryIntrigue 54 / 100

Levomilnacipran (Fetzima) is one mirror-image half of milnacipran, sold separately by Forest Pharmaceuticals in the US after FDA approval in 2013. It is unusual among SNRIs because it preferentially blocks the norepinephrine pump rather than the serotonin one, which is the opposite of duloxetine and venlafaxine. That noradrenergic emphasis was meant to deliver stronger effects on energy, motivation, and concentration in depressed patients. Trial data are favorable but not overwhelming, and the drug never gained the prescribing momentum of duloxetine. The parent compound milnacipran (the racemic mix) is widely used in Europe and Japan for depression and is approved in the US specifically for fibromyalgia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

A clean NET-selective SNRI probe with solid approval data and low novelty

Look, there are worse compounds to have in a library than levomilnacipran, but lets be direct: the SNRI class in 2026 is not where you go to find frontier pharmacology. Duloxetine, venlafaxine, desvenlafaxine — the space is crowded, mature, and the clinical effect sizes in MDD are modest across the board. What levomilnacipran does have, and what keeps it from being completely unremarkable, is its inverted selectivity. NET affinity at roughly 11 nM beats SERT at roughly 19 nM, which is the opposite of every other major SNRI on the market. That matters when youre trying to dissect norepinephrine versus serotonin contributions to an effect in a rodent model or a mechanistic human study.

The pharmacokinetic profile is genuinely clean. Mostly renal excretion, minimal CYP3A4 metabolism, near-zero off-target activity at adrenergic, dopaminergic, muscarinic, or histaminergic receptors. For pharmacology work where you want to isolate transporter blockade without confounding receptor hits, thats useful. Its the closest thing to a reference standard NET-preferring SNRI the field has, which is a narrow but real distinction.

Where it scores poorly is novelty and mechanism promise. The compound was approved by the FDA in 2013. Thats not a criticism — FDA approval means real phase 3 evidence, which the evidence and translational scores reflect — but it does mean the interesting questions have mostly been asked. If you want to understand NE reuptake inhibition in the clinic, the semaglutide-equivalent paradigm shift moment for SNRIs never arrived, and levomilnacipran didnt change that. We think the research attention it still generates is almost entirely as a comparator or a probe, not because anyone expects a surprise finding from the compound itself.

Honestly, the differentiation score is the most interesting conversation. Reboxetine is more NET-selective, but reboxetine has a problematic efficacy record in humans and regulatory problems in the US. Atomoxetine is NET-selective but carries pediatric ADHD baggage that complicates off-label use in adult neuropsychiatric research. Levomilnacipran sits in the middle: approved, clean, accessible, usable. For a lab running a study on noradrenergic contributions to cognitive function or pain modulation, it is probably the reference arm you reach for. Thats worth something. Its just not worth a lot in 2026 when the real action in CNS pharmacology is happening at psychoplastogen, kinase modulator, and mitochondrial peptide addresses.

If your program specifically needs a NET-biased SNRI with a clean off-target profile and real human pharmacokinetic data, levomilnacipran earns its shelf space. For anyone else, it sits comfortably in the established-mature tier: competent, useful in the right context, and not a reason to change your research agenda.

Novelty

22

Mechanism promise

35

In-category differentiation

48

Evidence quality

72

Translational signal

65

Research bench value

58

Rationale Approved in 2013 with a real clinical evidence base, levomilnacipran earns credit for NET > SERT selectivity as a research tool, but the SNRI class is deeply mature and the compound itself introduces no new mechanism. Evidence and translational scores pull the overall up from what its novelty and mechanism scores deserve; bench value is legitimate but limited to NE/SERT dissection work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pure SNRI ((1S,2R)-enantiomer)

The (1S,2R)-enantiomer of milnacipran; a pure SNRI with strong NET selectivity over SERT and minimal off-target activity.

Abstract

Levomilnacipran ((1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; CAS 96847-55-1 (HCl salt); molecular formula C15H22N2O; molecular weight 246.35) is the (1S,2R)-enantiomer of milnacipran, marketed as Fetzima by Forest Pharmaceuticals after FDA approval in 2013. Distinct among SNRIs for inverse selectivity: NET affinity (Ki approximately 11 nM) exceeds SERT affinity (Ki approximately 19 nM) by approximately 2-fold, the opposite of duloxetine and venlafaxine. The compound has minimal off-target activity at adrenergic, dopaminergic, muscarinic, or histaminergic sites. Plasma half-life is approximately 12 hours; metabolism is primarily renal (excreted unchanged) with minor CYP3A4 contribution, producing minimal drug-drug interaction potential. Approved for major depressive disorder; off-label investigation in attention deficit and chronic pain conditions. The dosing form is extended-release; 40 to 120 mg once daily. Used as the reference NET-selective SNRI in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-213Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vilazodone

Plain-language summaryIntrigue 53 / 100

Vilazodone (Viibryd) is an antidepressant from Forest Pharmaceuticals, approved in 2011, designed to do two things at once: block the serotonin pump like an SSRI and also directly partially activate the 5-HT1A serotonin receptor. The theory was that hitting 5-HT1A directly would short-circuit the slow autoreceptor desensitization process that normally delays SSRI response by several weeks. In practice the speed advantage in trials has been modest, and the drug has not displaced standard SSRIs as a first-line option. It does have somewhat lower rates of sexual dysfunction than SSRIs, which is its main practical selling point. Must be taken with food (at least 500 calories) for adequate absorption. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

FDA-approved dual-mechanism antidepressant with real pharmacology but limited frontier research appeal

Look, vilazodone is a real drug with a real rationale. The idea behind it is sound: block SERT to raise synaptic serotonin, and simultaneously activate 5-HT1A autoreceptors directly so you dont have to wait weeks for those autoreceptors to desensitize on their own. That delay is one of the genuine frustrations with plain SSRIs, and Forest Pharmaceuticals actually tried to engineer around it. That kind of mechanistic intentionality is worth acknowledging.

The problem is that the clinical payoff was modest. The faster-onset hypothesis showed up in some trial data but hasnt become a defining feature of how clinicians actually use the compound. The PETAL studies and subsequent Phase 3 work confirmed MDD efficacy — theres no question it works — but the differentiation story got muddier after vortioxetine arrived in 2013 with an even broader receptor profile (SERT, 5-HT1A, 5-HT1B, 5-HT3, 5-HT7) and a more compelling case for cognitive symptom improvement. At that point, vilazodone became the simpler version of the multi-target antidepressant concept rather than its leading example.

From a bench perspective, vilazodone does carry real value as a reference probe. If you’re designing experiments to dissect combined SERT inhibition plus 5-HT1A partial agonism — specifically trying to separate those two contributions to a behavioral or molecular endpoint — vilazodone gives you a clean, well-characterized tool with published pharmacokinetics and known receptor affinities (SERT Ki ~0.1 nM, 5-HT1A Ki ~0.2 nM, intrinsic activity ~70%). Thats not nothing. The CYP3A4 metabolism and the food-effect on bioavailability are well-documented, which makes dosing in animal models somewhat more predictable.

What we dont think is that vilazodone represents a current research priority. The antidepressant mechanism space has moved on. The interesting questions now involve psychoplastogens, BDNF-TrkB direct agonism, AMPA potentiation, and neuroinflammatory targets. Vilazodone is an approved drug, which means its evidence base is solid, but solid evidence on a mature mechanism in a saturated class isnt the same as a compelling research target. For investigators specifically studying 5-HT1A partial agonism pharmacology, it remains a useful reference. For everyone else, its a clinical compound that belongs in formularies, not on the short list of compounds worth bench time in 2025.

Honestly, the score of 50 reflects exactly what it is: competent, approved, well-understood, and no longer at the frontier of anything.

Novelty

28

Mechanism promise

55

In-category differentiation

40

Evidence quality

72

Translational signal

65

Research bench value

45

Rationale Vilazodone’s combined SERT + 5-HT1A partial agonism is genuine pharmacological thinking and the rubric explicitly places dual SERT/5-HT1A in the 50-70 mechanism range, but its novelty is low as a 2011-approved drug with mature literature, and vortioxetine has meaningfully outpaced it on multi-receptor differentiation. Strong evidence quality from Phase 3 RCTs props the overall up, but this is not a frontier target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

SSRI + 5-HT1A partial agonist

A dual-mechanism antidepressant combining SSRI activity with 5-HT1A partial agonism intended to accelerate clinical response.

Abstract

Vilazodone (5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide; CAS 163521-12-8; molecular formula C26H27N5O2; molecular weight 441.53) is an SSRI plus 5-HT1A partial agonist developed at Merck KGaA and Forest Pharmaceuticals, approved by the FDA in 2011 under the trade name Viibryd. SERT affinity is approximately 0.1 nM; 5-HT1A affinity is approximately 0.2 nM (intrinsic activity approximately 70 percent), producing partial agonism at the autoreceptor. The dual mechanism was designed to bypass the autoreceptor desensitization period that delays SSRI response: by directly activating 5-HT1A receptors while blocking SERT, vilazodone aims to produce faster clinical effect. Real-world clinical trials have shown modest response acceleration. Plasma half-life is approximately 25 hours; metabolism is via CYP3A4 (primary). Approved for major depressive disorder. The compound is administered with food, which doubles bioavailability compared to fasted dosing. Used as a reference compound for 5-HT1A partial agonist plus SSRI pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-212Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 43 44 45 46 47 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.